Javara, Nevada Health Centers Announce Partnership
Javara has announced a strategic partnership with Nevada Health Centers (NVHC). Javara will employ and embed clinical research professionals within NVHC clinics to work alongside physicians and medical staff, providing aspects of operational collaboration to deliver clinical trials as a care option to their patients. The immediate focus of this new partnership is the NVHC Reno and Carson City locations. Javara and NVHC anticipate activation of the first clinical trials in internal medicine in the fall of 2023.
“As an FQHC (Federally Qualified Health Center), many patients served by Nevada Health Centers are from regions and demographic groups that have traditionally been sorely underrepresented in clinical trials,” said Jennifer Byrne, Javara founder and CEO. “Javara is grateful for the trust of Nevada Health Centers to bring access to novel treatments and innovative health care options to these communities for the first time. With a special focus on those patients with unmet medical needs in geographically isolated and otherwise marginalized regions, we are fully committed to the community benefit this partnership brings.”
“When seeking a partner to guide Nevada Health Centers’ efforts to develop a clinical trials program for our patients, Javara most closely aligned with our organizational mission and vision,” said Walter Davis, Nevada Health Centers' CEO. “We are a safety net provider for the community, and many of our patients live with chronic conditions. This partnership enables us to offer both access to innovative treatments and advanced education to our patients and establish a greater sense of trust in research. We are excited to be positioned as a contributor to the scientific knowledge base that helps improve the delivery and understanding of medicine.”
Reference
Javara, Nevada Health Centers Announce Partnership to Bring Clinical Research to the Geographically Isolated, Medically Underserved. (2023, August 7). Business Wire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
